Skip to main content
. Author manuscript; available in PMC: 2019 Jan 4.
Published in final edited form as: Nature. 2018 Jul 4;560(7719):499–503. doi: 10.1038/s41586-018-0343-4

Figure 1: Treatment with PI3K inhibitors causes systemic feedback resulting in increases in blood glucose and insulin.

Figure 1:

(A) Mean Blood glucose and (B) insulin levels with standard deviation in mice treated with the indicated PI3K inhibitor compounds (N=5/arm, p-value <0.0001 by Two-Way ANOVA for all curves as compared to vehicle). (C) Mean with standard deviation of c-Peptide levels assessed at 240 min (p-values comparing vehicle treatment to BKM120, BYL-719, and GDC-0032 by two sided t-test were 0.017, <0.0001, and 0.007 respectively). (D) Mean percent of FDG-PET signal with standard deviation of orthotopically implanted KPC tumors imaged 90 minutes after a single treatment with BKM120 (N=4/arm, p-value =0.0002, by two sided t-test).